Lysine residues on autologous melanoma cell surface proteins

Lysine residues on autologous melanoma cell surface proteins serve as the primary chemical attachment points for haptens, such as dinitrophenyl (DNP), in specific cancer immunotherapy protocols. By covalently bonding to the ε-amino groups of these lysine residues, the hapten modifies the biochemical profile of the patient's own tumor cells, effectively making them appear foreign to the immune system. This process, known as haptenization, is designed to break immune tolerance by enhancing the processing and presentation of tumor-associated antigens to T-lymphocytes. In clinical practice, autologous melanoma cells are harvested, modified at these lysine sites, and then re-administered as a vaccine to stimulate a robust anti-tumor immune response. This approach has been shown to induce delayed-type hypersensitivity reactions and the production of specific antibodies, which are often associated with improved clinical outcomes in patients with advanced melanoma (Berd et al., 1986; Berd et al., 2004).

Other names

Surface lysine residuesDNP-modified tumor proteinsHapten-modified autologous tumor antigens

Haptenization: Covalent modification of primary amines on lysine residues with a hapten (e.g., DNP) to increase the immunogenicity of tumor-associated antigens and stimulate a T-cell mediated immune response.